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BACKGROUND AND PURPOSE
Thermostabilization by mutagenesis is one method which has facilitated the determination of high-resolution structures of the
adenosine A2A receptor (A2AR). Sets of mutations were identified, which both thermostabilized the receptor and resulted in
preferential agonist (Rag23 mutant) or antagonist (Rant5 and Rant21) binding forms as assessed by radioligand binding
analysis. While the ligand-binding profiles of these mutants are known, the effects these mutations have on receptor
activation and downstream signalling are less well characterized.
EXPERIMENTAL APPROACH
Here we have investigated the effects of the thermostabilizing mutations on receptor activation using a yeast cell growth
assay. The assay employs an engineered Saccharomyces cerevisiae, MMY24, which couples receptor activation to cell growth.
KEY RESULTS
Analysis of the receptor activation profile revealed that the wild-type (WT) A2AR had considerable constitutive activity. In
contrast, the Rag23, Rant5 and Rant21 thermostabilized mutants all exhibited no constitutive activity. While the preferentially
antagonist-binding mutants Rant5 and Rant21 showed a complete lack of agonist-induced activity, the Rag23 mutant showed
high levels of agonist-induced receptor activity. Further analysis using a mutant intermediate between Rag23 and WT
indicated that the loss of constitutive activity observed in the agonist responsive mutants was not due to reduced G-protein
coupling.
CONCLUSIONS AND IMPLICATIONS
The loss of constitutive activity may be an important feature of these thermostabilized GPCRs. In addition, the constitutively
active and agonist-induced active conformations of the A2AR are distinct.
Abbreviations
3AT, 3-aminotriazole; A2AR, adenosine A2A receptor; FDGlu, fluorescein-Di-b-D-glucopyranoside; ICL3, third intracellular
loop; WT, wild-type; YNB, yeast nitrogen base
Introduction
GPCRs form a large family of cell surface receptors mediating
cellular responses to a wide range of external stimuli includ-
ing hormones, neurotransmitters, odourants and nucleotides
(Gloriam et al., 2007). GPCRs have a highly conserved archi-
tecture; however, the sequence homology is low particularly
in the extracellular loop regions, most likely as a result of the
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requirement for recognition and binding of a wide range of
ligands (Peeters et al., 2011). Binding of a cognate ligand to
the specific binding site of the receptor initiates a conforma-
tional change allowing recruitment and activation of the
receptor specific G-protein, which in turn initiates an intra-
cellular signalling cascade. GPCRs exhibit significant confor-
mational flexibility reflecting a number of functional states
(Kobilka and Deupi, 2007). Agonists cause full activation of
the receptor; however, partial agonists induce submaximal
activation of the G-protein even at saturating concentrations.
In addition, it is well documented that many GPCRs exhibit
constitutive, agonist-independent activity (Milligan et al.,
1995; Strange, 2002; Gloriam et al., 2007). Antagonists
inhibit ligand binding but do not affect constitutive activity,
while inverse agonists decrease constitutive activity.
There have beenmarked advances in our understanding of
the mechanism of action of GPCRs in the last 4 years or so as
a result of the high-resolution structures of several receptors in
a number of different states. Significant progress has been
made through the development of GPCR fusion proteins,
where a T4 lysozyme replaces the conformationally dynamic
third intracellular loop (ICL3), for example (Cherezov et al.,
2007; Jaakola et al., 2008; Chien et al., 2010; Wu et al., 2010;
2012; Shimamura et al., 2011; Xu et al., 2011; Granier et al.,
2012; Thompson et al., 2012). In each case, the insertion was
essential for obtaining well-diffracting crystals with the T4
lysozyme mediating the crystal contacts. The solved struc-
tures have provided unprecedented detail of the binding sites
of the individual receptors, highlighting key receptor-specific
differences and the first definitive insight into the conforma-
tional changes involved in switching between agonist- and
antagonist-bound states. One recent addition to the structural
gallery is the complex of the b2 adrenoceptor together
with the heterotrimeric Gs, which revealed conformational
changes in both the receptor and G-protein occurring upon
association (Rasmussen et al., 2011).
An alternative approach involves alanine-scanning muta-
genesis coupled with radioligand-binding analysis after
heating the receptor in order to identify mutants with
retained function but increased thermostability. This
approach has been applied to three receptors to date, the
turkey b1 adrenoceptor (Serrano-Vega et al., 2008), the adeno-
sine A2A receptor (A2AR) (Magnani et al., 2008) and the neuro-
tensin 1 receptor (Shibata et al., 2009). In each case,
combinations of a small number of point mutations resulted
in receptor forms with significantly increased thermostability
and greater stability in small chain detergents compared with
the WT. The thermostabilized turkey b1 adrenoceptor was
subsequently successfully crystallized, and a number of high-
resolution structures solved (Warne et al., 2008; 2011). An
agonist-bound structure of thermostabilized mutant A2AR was
also recently solved (Lebon et al., 2011). One issue with this
method is that while the thermostabilizing mutations are
transferable between highly homologous receptors, e.g. the b1
and the b2 adrenoceptors (Serrano-Vega and Tate, 2009), it has
so far not been possible to transfer between more distantly
related receptors and, thus, a complete alanine scan must be
completed for each receptor. While these structures have
significantly advanced our understanding of the structure–
function relationships of GPCRs, they are essentially static
snapshots of the receptors and lack information on the
dynamic changes of these molecules. Also, the structures have
generally been of receptors highly engineered either through
the insertion of T4 lysozyme in the ICL3, or by the introduc-
tion of stabilizingmutations. The effect of thesemodifications
on the receptor-signalling function has not typically been
described. Indeed, the replacement of the ICL3 with T4 lys-
ozyme in the vast majority of the GPCR structures determined
has prevented characterization of signalling function.
In this study, we aimed to explore the molecular basis of
stabilization of the A2AR, one of a group of receptors respon-
sible for mediating cellular responses to the purine nucle-
oside, adenosine. We used previously described thermostable
mutants with a preference for either the agonist- (Rag23) or
antagonist-binding conformations (Rant5, Rant21) (Magnani
et al., 2008) and a yeast cell growth assay, which can distin-
guish between constitutive and agonist-induced receptor acti-
vation. The results presented in this manuscript provide the
first report of how these modifications affect receptor activa-
tion and reveal that in the case of these mutant receptors,
inhibition of constitutive activity is correlated with receptor
thermostabilization.
Methods
Materials
Yeast nitrogen base (YNB) and yeast extract were purchased
from Difco (Franklin Lakes, NJ, USA). Peptone, L-histidine,
EDTA, EGTA, BSA, Folin-Ciocalteau reagent, amino acids,
3-aminotriazole (3AT) and theophylline were obtained from
Sigma-Aldrich (Gillingham, UK), and dimethyl sulfoxide
from Acros Organics (Geel, Belgium). Scintillation cocktail
(Ultima Gold MV) and [3H]NECA were obtained from Perk-
inElmer (Cambridge, UK). [3H]ZM241385 was purchased
from American Radiolabelled Chemicals Inc. (Stevenage, UK)
while ZM241385 and NECA were obtained from Tocris
(Abingdon, UK). GF/B filters were purchased from Whatman
(Maidstone, UK). The Lightning Quikchange site-directed
mutagenesis kit was obtained from Stratagene/Agilent (Stock-
port, UK). Fluorescein-Di-b-D-glucopyranoside (FDGlu) was
purchased from Invitrogen (Paisley, UK).
Construct generation and mutagenesis
Rant5, Rant21 and Rag23 A2AR mutants were obtained from
GeneArt (Regensburg, Germany). All synthetic genes encoded
the full-length A2AR gene and contained a FLAG tag at the N
terminus. The genes were cloned into the pDDGFP Saccharo-
myces cerevisiae expression plasmid (Newstead et al., 2007).
The construct comprises the receptor gene upstream of the
gene coding for GFP-His8. The pDDGFP plasmids were then
digested using BamHI and HindIII, which excised the com-
plete gene coding for the A2AR + GFP-His8 fusion proteins.
These genes were then ligated into the integrating p306GPD
(Dowell and Brown, 2009) vector. The wild-type (WT) A2AR
and intermediate mutants were generated from either the
Rant5 or Rag23 synthetic genes by site-directed mutagenesis
using the QuickChange Lightning Site-Directed Mutagenesis
kit and the primers detailed in Supporting Information
Table S1. The single and double mutants intermediate
between Rant5 and WT are indicated by the mutant name.
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The Rag23-A208L mutant was generated by mutating the
A208 of Rag23 back to the WT Leu residue.
Expression
All the A2AR constructs were fusions with a C-terminal GFP-
8His tag in the p306GPD vector, transformed using the
lithium-acetate procedure (Gietz and Schiestl, 2007) and
chromosomally integrated at the ura3 locus in the MMY24
(MATa fus1::FUS1-HIS3 LEU2::FUS1-lacZ far1 sst2 ste2
gpa1::ADE2 his3 ura3 trp1 Gpa1p/Gai3) yeast strain (Dowell
and Brown, 2009). The WT and Rag23-A208L constructs were
also transformed into the MMY11 (MATa fus1::FUS1-HIS3
LEU2::FUS1-lacZ far1 sst2 ste2 gpa1::ADE2 his3 ura3 trp1) yeast
strain. Estimation of the expression levels for all the con-
structs using GFP as previously described (Newstead et al.,
2007) gave values between 0.7 and 1.6 mg·mL-1 (Supporting
Information Table S2).
Yeast growth assay
A yeast cell growth assay was used to analyse the G-protein
coupling and activation of the different A2AR constructs. This
assay utilizes a modified S. cerevisiae strain, MMY24 (Brown
et al., 2003), which has been genetically engineered to allow
functional characterization of heterologous GPCRs. In this
strain, the gene encoding for Ste2p, the only yeast GPCR
capable of coupling to this pathway in a haploid cell, was
deleted and a chimaeric Ga subunit was introduced in which
the five C-terminal amino acids of the yeast Ga protein Gpa1p
were replaced with the corresponding residues from mamma-
lian Gai3 (Brown et al., 2003). Receptor activation induces a
reporter gene (FUS1-HIS3) in which HIS3, encoding the bio-
synthetic enzyme imidazoleglycerol-phosphate dehydratase,
is under control of the pheromone-responsive FUS1 promoter.
Activation of the pathway by GPCR agonism allows the yeast
to grow in media lacking histidine. Hence, growth of the cells
in the absence of histidine but the presence of receptor spe-
cific agonist provides a measure of receptor activation and
signalling. Growth of the cells is measured by changes in the
levels of fluorescein, the product of the reaction between
FDGlu and exoglucanase, an endogenous yeast enzyme
secreted from dividing cells (Dowell and Brown, 2009). The
mutants expressed in MMY24 were inoculated into –URA
media (6.7% YNB, 2% D-glucose, 1.26 g·L-1 amino acid
supplement [23.53 mg of L-arginine (HCl), 117.6 mg of
L-aspartic acid, 117.6 mg of glutamic acid (monosodium),
35.29 mg of L-lysine, 23.53 mg of L-methionine, 58.82 mg
of L-phenylalanine, 441.2 mg of L-serine, 235.3 mg of
L-threonine, 35.29 mg of L-tyrosine and 176.5 mg of
L-valine]) supplemented with histidine to a final concentra-
tion of 20 mg·L-1, and cultured overnight at 30°C. The cul-
tures obtained were diluted into –URA media supplemented
with 26.1 mM Na2HPO4·7H2O, 21.1 mM NaH2PO4, pH 7.0 to
an OD600 of 0.02. The assay mix was supplemented with 3AT,
to a final concentration of 5 mM. 3AT is an inhibitor of the
imidazoleglycerol-phosphate hydratase. This was calibrated
to eliminate background activity from the FUS1-HIS3 reporter
in the absence of GPCR, therefore ensuring that the responses
obtained are a measure of receptor signalling (Supporting
Information Fig. S1). Adenosine deaminase was not added to
the assay mix as preliminary experiments demonstrated that
this did not make any difference to the receptor activity (data
not shown). FDGlu, a substrate of exoglucanase, an endog-
enous yeast enzyme secreted from dividing cells, was also
added to the medium to a final concentration of 20 mM. The
product of this reaction is the fluorescent molecule, fluores-
cein. An increase in fluorescence (excitation wavelength =
485 nm, emission wavelength = 535 nm) is thus a measure of
growth of the culture. Different concentrations of agonist
(0.17–0.2 mM) were added. The yeast growth was measured
by fluorescence measurement using a microplate reader
(TECAN Ultra Evolution, Reading, UK) following 23 h incu-
bation at 30°C. Log10 [NECA] against fluorescence curves were
plotted and fitted to non-linear regression, providing EC50
values. Data were analysed using GraphPad Prism 5.0 (Graph-
Pad Software, San Diego, CA, USA).
Radioligand binding analysis
Yeast membranes were prepared as previously described
(Singh et al., 2008). Saturation and competition binding
assays were carried out as described previously (Singh et al.,
2010). In brief, for saturation assays, membranes expressing
the WT or mutant A2AR forms were incubated with
[3H]ZM241385 (0.036–20 nM) or [3H]NECA (0.3–300 nM) in
binding buffer (20 mM HEPES pH 7.4, 1 mM EDTA, 1 mM
EGTA, 0.1% BSA). Non-specific binding was defined in the
presence of 10 mM theophylline at each concentration. In
separate experiments, the WT and Rag23-A208L membranes
from both the MMY11 and MMY24 strains prepared in the
absence of NaCl were incubated with [3H] NECA (0.3–
300 nM) in an alternative binding buffer (20 mM HEPES pH
7.4, 1 mM EDTA, 1 mM EGTA, 0.1% BSA, 10 mM MgCl2).
Non-specific binding was defined in the presence of 10 mM
theophylline at each concentration. Assays were performed at
least in duplicate in a final volume of 1 mL containing 20 mg
of membrane protein in each tube. The reactions were incu-
bated for 3 h at room temperature and receptor-bound radio-
ligand was collected by filtration through Whatman glass
micro-fibre GF/C filters. The filters were allowed to soak in
2 mL Ultima GoldTM XE scintillation fluid for at least 6 h
before the radioactivity was determined using an LS 6500
Beckman Coulter scintillation counter. Agonist competition
binding profiles for the WT and mutant receptor forms were
determined by competition-binding assay. About 20 mg of
membrane protein containing WT and mutant A2AR was
incubated with a fixed concentration of [3H]ZM241385 (2 nM
for WT and Rant5 and 21 and 9 nM for Rag23) and varying
concentrations of competing NECA (100 mM to 1 nM for WT
and Rag23 and 10 mM to 10 nM for Rant5, Rant21 and T88A)
or adenosine (10–10 nM), in a final volume of 1 mL binding
buffer. Non-specific binding was defined in the presence of
10 mM theophylline. Initiation, incubation and termination
procedures were as described for the saturation-binding assay.
Results
The thermostabilized Rag23, Rant5
and Rant21 mutants exhibit no
constitutive activity
The WT A2AR as well as the Rant 5 (A54L, T88A, V239A), Rant
21 (A54L, T88A, K122A, V239A) and Rag 23 (F79A, A184L,
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R199A, L208A, L272A) and intermediate mutants (Tables 1
and 2) were expressed in an engineered S. cerevisae strain,
MMY24, in which receptor activation is coupled to yeast cell
growth. The cells were treated with different concentrations
of NECA, ranging from 0.5 to 0.2 mM; and fluorescence
measurements were taken following incubation for 23 h at
30°C. The WT receptor exhibits high levels of constitutive
activity, observed as cell growth in the absence of any recep-
tor agonist (Figure 1, Table 1). The constitutive activity
accounts for more than 50% of the total activity of the WT
receptor. It is possible to at least partially inhibit the consti-
tutive activity with inverse agonists (Supporting Information
Fig. S2). Addition of the A2AR agonist, NECA, stimulates
further activity of the WT receptor in a concentration-
dependent manner (EC50 = 33 ! 7 nM; Figure 1; Table 1). The
Rag23 thermostabilized agonist-conformation mutant shows
slightly more potent agonist-dependent receptor activity
compared with WT (EC50 = 13 ! 1 nM; Figure 1; Table 1). The
thermostabilized antagonist-conformation mutants, Rant5
and Rant21, show no agonist-induced receptor activity. In
contrast to the WT, Rag23, Rant5 and Rant21 show no con-
stitutive activity (Figure 1, Table 1). Saturation binding analy-
sis of the WT, Rag23, Rant5 and Rant21 mutants revealed that
all the receptor forms exhibit high-affinity binding for the
antagonist ZM241385. The specific activities of the mutants
show that the functional expression level (Bmax; Supporting
Information Table S2) of each of the mutants is higher than
that of the WT receptor, indicating that the loss of constitu-
tive activity observed is not due to low functional expression.
The affinity of the Rag23 for ZM241385, the thermostabilized
agonist-binding form, was reduced by an order of magnitude
compared with the WT, Rant5 and Rant21 receptor forms
(Table 1, Figure 2). This is in agreement with results reported
for expression of these receptor forms in Escherichia coli
(Magnani et al., 2008). However, the precise Kd values
obtained in the yeast expression system described here are
lower than those reported for the same constructs expressed
in E. coli. The Kd value for the WT receptor reported here is
consistent with that obtained for the A2AR heterologously
expressed in Pichia pastoris (Singh et al., 2010), S. cerevisiae
(O’Malley et al., 2007), CHO cells (Uustare et al., 2005) and
A2AR present in rat brain tissue (Alexander and Millns, 2001).
Competition-binding analysis revealed that while Rag23
bound the agonist NECA with a reduced Ki compared with
the WT (Table 1), the Rant5 and Rant21 had dramatically
increased Ki values (Table 1, Figure 2). These results are con-
sistent overall with the binding data obtained for the same
receptor constructs expressed in E. coli (Magnani et al., 2008).
T88 has a major role in mediating
NECA binding
Analysis of the mutants intermediate between Rant5 and WT
reveals that the A54L mutant has reduced constitutive activ-
ity compared with WT. In addition, while this mutant exhib-
its agonist-dependent receptor activity, it is less sensitive to
NECA than the WT receptor or the Rag23 mutant (EC50 = 0.10
! 0.01 mM; Figure 3, Table 2). The V239A mutant shows
lower sensitivity to NECA than A54L (EC50 = 3.54 ! 0.22 mM;
Figure 3, Table 2) and has no detectable constitutive activity,
indicating that the V239 residue plays a crucial role in both
agonist-induced and constitutive activities. The A54L +
V239A mutant shows an almost identical activities profile to
Table 1
Ligand binding and activation profiles for the Rag and Rant mutants
Receptor
form
[3H] ZM241385
Kd ! SEM (nM)
NECA
Ki ! SEM (mM)
[3H] NECA Kd ! SEM (nM)*a
NECA
EC50 ! SEM (nM)
Constitutive activity
! SEM (% of max
activity of WT)+G-protein -G-protein
WT 0.85 ! 0.08 1.01 ! 0.23 8.6 ! 3.7 123.9 ! 7.1 33 ! 7 54.8 ! 1.5
Rag23 6.32 ! 0.34 0.18 ! 0.02 – – 13 ! 1 6.1 ! 0.9
Rag23-A208L 7.49 ! 0.90 – 1.6 ! 0.2 14.4 ! 1.3 31 ! 3 3.6 ! 0.2
Rant5 0.74 ! 0.05 531 ! 300 – – ND 5.3 ! 0.4
Rant21 0.63 ! 0.09 247 ! 18 – – ND 3.5 ! 0.2
*Kds for [3H] NECA were obtained for both the WT and the Rag23-A208L mutant.
aThe WT and Rag23-A208L receptor forms were expressed both in the presence and absence of G-protein in the MMY24 and MMY11 yeast
strains respectively.
ND, no detectable activity; –, not determined.
Table 2
Activation profile of the single and double mutants intermediate
between Rant5 and WT A2AR
Receptor form
NECA
EC50 ! SEM
(mM)
Constitutive activity
! SEM (% of max
activity of WT)
WT 0.033 ! 0.007 54.8 ! 1.5
A54L 0.100 ! 0.007 25.0 ! 1.1
T88A ND 39.8 ! 2.3
V239A 3.5 ! 0.2 2.5 ! 0.1
A54L + T88A ND 46.4 ! 4.5
A54L + V239A 4.9 ! 0.5 2.6 ! 0.1
T88A + V239A ND 3.4 ! 0.3
ND, no detectable activity.
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that of the single V239A mutant, while the T88A + V239A
mutant shows a complete loss of both constitutive and
agonist-dependent activities (Figure 3, Table 2). The T88A
mutant also exhibits high levels of constitutive activity,
although slightly lower than that observed for the WT, but
showed no NECA-induced activity (Figure 4, Table 3). How-
ever, stimulation with adenosine induced low but detectable
receptor activity (Figure 4, Table 3). The biphasic nature of
the T88A adenosine dose–response curve is not due to toxic-
ity of the adenosine (data not shown) but rather to an unex-
plained pharmacological effect. A similar profile was obtained
for ligand binding with the T88A, showing a fivefold reduc-
tion in affinity for adenosine and a ~200-fold reduction in
affinity for NECA compared with WT (Table 3). Together,
these data indicate that the T88A mutant is capable of under-
going the conformational change associated with ligand-
mediated activation, but has lost affinity for these ligands.
Loss of constitutive activity observed in the
Rag23 is not due to the ICL3 mutant L208A
The fact that Rag23 has no constitutive activity but exhibits
NECA-induced activity suggests that the constitutively active
Figure 1
NECA-induced activity of the thermostabilized mutant A2AR constructs (A) Rag23, Rag23-A208L and (B) Rant5 and Rant21 compared with WT.
The maximum response of the WT receptor was taken as 100%, and the response obtained from the cells with no receptor was taken as 0%. The
different receptor forms were expressed in the MMY24 Saccharomyces cerevisiae strain as constructs in the p306GPD vector. Data points are the
average of three different experiments (two different experiments only for the Rag23-A208L mutant) performed in triplicate.
Figure 2
Saturation binding of [3H] ZM241385 and binding of the low-affinity agonist NECA in competition with [3H]ZM241385 to Saccharomyces cer-
evisiae MMY24 membranes expressing the WT (A), Rag23 (B), Rant5 (C) and Rant21 (D) A2AR constructs. All data are representative of two
independent experiments performed in triplicate. Kd values were derived by non-linear regression analysis of the saturation binding data. The
competition binding data were fitted to a one binding site model. Ki values were derived from experimentally determined IC50 values. Mean data
! SEM are presented in Table 1.
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receptor conformation is different from that of the agonist-
induced conformation. A closer inspection of the five muta-
tions, which combine to make the Rag23, revealed that one
of these, L208A, is located in ICL3. As this region of the
receptor is known to have an important role in G-protein
coupling, we explored whether this residue is the key in
mediating constitutive activity. We generated a mutant inter-
mediate between Rag23 and the WT, Rag23-A208L (F79A,
A184L, R199A, L272A), in which Ala208 has been back-
mutated into the original Leu. Functional analysis revealed
that the Rag23-A208L mutant has no constitutive activity
(Figure 1, Table 1), indicating that L208 has little or no role in
mediating this activity. However, interestingly, the Rag23-
A208L exhibits much higher agonist-induced efficacy than
Rag23. Indeed, the Rag23-A208L exhibits close to the
maximum WT levels of activity in response to NECA
(Figure 1).
Differences in levels of constitutive activity
are not the result of altered coupling
to G-protein
It is possible that the lack of observed constitutive activity of
the Rag23 and Rag23-A208L is the result of altered G-protein
coupling for these mutants. The high efficacy of the Rag23-
A208L mutant is strongly suggestive that the lack of consti-
tutive activity seen in this mutant is not the result of reduced
G-protein coupling. However, in order to investigate this
further, we explored the binding of the WT and the Rag23-
A208L to [3H] NECA in the presence and absence of the
G-protein. This was achieved by also expressing the receptor
variants in an alternative yeast strain MMY11 (Olesnicky
et al., 1999), genetically identical to MMY24 but lacking the
G-protein alpha subunit. It is known that the presence of
G-protein increases the affinity of a receptor for agonist by
placing the receptor in a high-affinity binding conformation.
If G-protein coupling had not been altered in the Rag23-
A208L mutant, we would expect to see approximately the
same level of reduction in affinity for [3H] NECA in the
absence of G-protein for both the mutant and WT receptor
forms. The data revealed that for the WT receptor, the
absence of G-protein reduced the affinity for NECA by
approximately an order of magnitude confirming that Ga
affects the affinity state for the ligand. However, the binding
affinity for [3H] NECA for Rag23-A208L in the absence of
G-protein was also reduced by approximately an order of
magnitude compared with the binding affinity in the pres-
ence of G-protein (Table 1), indicating that the basis for this
mutant’s lack of constitutive activity is not simply attribut-
able to failure to bind G-protein.
Discussion and conclusions
In the yeast cell growth-based assay, a heterologous GPCR is
isolated from its native environment and can be studied in
combination with a single G-protein species in a completely
defined system. This allows simple and rapid assessment of
mechanistic aspects of GPCR activation. Here, we profiled the
WT A2AR in addition to the previously reported Rag23, Rant5
and Rant21 mutants (Magnani et al., 2008) in order to obtain
a greater understanding of the molecular basis of their ther-
mostabilization. We selected experimental conditions in
which yeast growth was entirely dependent on GPCR activa-
tion and constitutive activity could be clearly observed. The
constitutive activity of the A2AR in our experiments compared
reasonably to values obtained in HEK293 cells as assessed by
cAMP accumulation in which constitutive activity accounted
for approximately a third of the maximal CGS21680-induced
activity (Klinger et al., 2002). Because the Rag23, Rant5 and
Rant21 receptor forms contain a number of point mutations,
we also generated various mutant forms intermediate
between the Rant5 and the WT. The results of this analysis
clearly demonstrate that while Rag23 retains high levels of
agonist-induced receptor activity, the Rant mutants exhibit
no discernable receptor activation. Although this finding is
in broad agreement with the previous study using only
Figure 3
Functional analysis of the mutants intermediate between WT A2AR and RANT5. The maximum response of the WT receptor was taken as 100%
and the response obtained from the cells with no receptor was taken as 0%. The single mutants A54L, T88A, V239A (A) and double mutants A54L
+T88A, A54L+V239A and T88A+V239A (B) are shown. The different receptor forms were expressed in the MMY24 Saccharomyces cerevisae strain
as C-terminal GFP fusion constructs in the p306GPD vector. In each case, the cells were treated with increasing concentrations of the A2AR agonist,
NECA. Data points are the average of three different experiments performed in triplicate.
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radioligand-binding analysis to characterize the mutants
(Magnani et al., 2008), here we present for the first time a
detailed activation profile for these mutants. One key obser-
vation was the total loss of constitutive activity for all three
mutant forms. On the basis of these data, it seems likely that
the loss of constitutive activity observed for all three mutant
receptors is a major contributory factor in their increased
thermostability. It should be noted that a recent agonist-
bound A2AR structure was obtained of a thermostabilized
mutant, GL31 (Lebon et al., 2011). In contrast to the findings
presented here, the thermostabilized GL31, which contains a
completely different set of point mutations to the Rag23
construct, exhibited WT levels of constitutive activity in a
mammalian cell signalling system. Thus, although in the case
Figure 4
Activity of the T88A mutant compared with WT A2AR (A, B). The maximum response of the WT receptor was taken as 100% and the response
obtained from the cells with no receptor was taken as 0%. The different receptor forms were expressed in the MMY24 Saccharomyces cerevisiae
strain as constructs in the p306GPD vector. The cells were treated with increasing concentrations of either NECA (A) or adenosine (B). Data points
are the average of three different experiments performed in triplicate. Structures of the NECA-bound (C, Pdb accession code 2YDV) and the
adenosine-bound (D, PDB accession code 2YDO) A2AR showing the position of the T88 residue relative to the bound ligand. The T88 side chain
and the ligands are shown in stick representations. The distances between the hydroxyl group of the T88 and the closest group of the two different
ligands are shown by the dotted lines.
Table 3
Comparison of the NECA and adenosine binding and activation profile of T88A
Receptor form
NECA Adenosine NECA Adenosine
Ki ! SEM (mM) Ki ! SEM (mM) EC50 ! SEM (nM) EC50 ! SEM (mM)
WT 1.01 ! 0.23 0.36 ! 0.01 33 ! 7 0.37 ! 0.02
T88A 187 ! 54 2.71 ! 0.06 ND 32 ! 3
ND, no detectable activity.
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of the Rag and Rant mutants thermostability correlates with
a loss of constitutive activity, there may be other mechanisms
by which thermostability can be achieved without the loss of
constitutive activity.
Analysis of the mutants intermediate between WT and
Rant5 revealed a clear trend in the characteristics of these
mutants with differing degrees of reduced agonist potency
and reduced/no constitutive activity. One of the intermediate
mutants T88A + V239A has no constitutive activity and no
signalling as observed for the Rant5 and Rant21 mutants.
Another intermediate mutant A54L + V239A exhibits no
constitutive activity and very low but measurable agonist-
induced signalling. The Tm for this receptor form in the
presence of antagonist was measured as 42°C compared with
46°C for Rant5 and 49°C for Rant21 (Magnani et al., 2008).
There is no reported Tm for the T88A + V239A mutant recep-
tor (Magnani et al., 2008) but given the lack of both consti-
tutive and agonist-induced signalling from this construct, it is
likely to be similar to the Rant5 and Rant21 mutants. It is
clear from the data that the effects of some of the intermedi-
ate mutations are additive. For example, the A54L + V239A
mutant has no constitutive activity but shows some agonist-
induced receptor activity. The A54L + T88A + V239A combi-
nation of the Rant5 has no constitutive activity and no
detectable agonist-induced receptor activity. It should be
noted that the Rant5 does bind NECA with much reduced
affinity. The conformation change induced by the mutations
is sufficient to prevent receptor activation but still allows
low-affinity binding of NECA. Other mutant combinations
do not appear to be additive, e.g. A54L + V239A, which has
the same receptor activity profile as the V239A-only mutant.
It may be that there is a benefit conferred by the A54L that is
not detectable by this assay.
Previous research has shown that mutating T88 dramati-
cally reduces both agonist-binding and agonist-induced
activities but does not significantly affect antagonist binding
(Jiang et al., 1996). The results presented here that support
these earlier findings, however, show that the degree to
which agonist activity is reduced is dependent on the agonist.
NECA failed to induce any receptor activity in the T88A
mutant while adenosine induced low but detectable activity.
Binding of the two ligands shows the same trend, indicating
that the impairment in agonism is due to a reduction of
affinity for these agonists. Clues to the precise molecular basis
of the difference in the responsiveness of the mutant to the
two agonists can be obtained from the recent A2AR structures
(Lebon et al., 2011). In the NECA-bound structure, the T88
forms a critical H-bond with the amide group on the ribose
ring of the ligand (Figure 4C). In contrast, the structure of the
adenosine-bound receptor reveals that T88 is too far away to
form a H-bond with the ligand (Figure 4D). Rather, this
residue, together with a number of others, appears to play a
role in stabilizing the protein via van der Waals interactions.
Although in our hands the T88A mutation seems critical for
the binding of NECA, the reversion of T88A back to Thr in
the thermostabilized A2AR construct that produced the
ZM-241385 co-structure did not restore NECA affinity. This
could be explained by the presence of other mutations pre-
venting the binding of NECA (Doré et al., 2011), suggesting
that the effects of these mutations are more complex than
initially thought.
The data presented here for Rag23, however, show that it
is possible to have very high levels of agonist-induced activity
and high ligand-binding affinity even when constitutive
activity has been abolished. Analysis of the Rag23-A208L
construct shows that this mutant also exhibits no constitu-
tive activity, indicating reversion to L208 alone is not enough
to restore constitutive activity. The fact that the Rag23-A208L
mutant exhibits maximal NECA-induced activity similar to
WT receptor suggests that the loss of constitutive activity
observed is not due to a reduction in G-protein coupling. This
was supported by radioligand-binding analysis performed
with [3H] NECA, which showed that the affinities of both the
WT and Rag23-A208L are reduced by the same amount in
the absence of G-protein. This is an important finding in view
of the known effects of G-protein interactions on GPCR
agonist affinities, and would be difficult to achieve in mam-
malian cells, which contain undefined G-protein species that
can not be selectively removed. Previous analysis of the ther-
mostabilizing mutants has been largely carried out by radio-
ligand binding to receptor expressed in E. coli. The data
shown here reveal that assessing the effects on downstream
signalling using a more informative eukaryotic cell system is
also important.
Previous research on the 5-hydroxytryptamine-4 receptor
(5-HT4R) indicates roles for a threonine residue in TM3
(Thr104) and a tryptophan residue in TM6 (Trp272) in the
formation of a so-called double toggle switch in stabilizing
the constitutively active conformation of the receptor
(Pellissier et al., 2009). Mutation of the Thr104 to an Ala leads
to a dramatic decrease in constitutive activity. A comparison
of the primary sequences indicates that Thr88 of A2AR is
equivalent to Thr104 of 5-HT4R. However, in the case of the
A2AR, mutation of Thr88 to an Ala has little effect on the
constitutive activity but a dramatic effect on agonist-induced
activity both for NECA and adenosine. In addition, the T88A
mutation is not present in either the Rag23 or Rag23-A208L
mutants, which also do not exhibit constitutive activity.
Therefore, the loss of constitutive activity observed in the
A2AR mutants must have a different mechanism than the one
proposed for 5-HT4R. Both the Rag23 and the Rant mutants
exhibit a complete loss of constitutive activity but contain no
common point mutations.
Of the individual point mutations generated, V239A
exhibits maintained agonist-induced activity but a loss of
constitutive activity. This residue is located on helix VI,
pointing towards helices III and V. It is possible that the
reduction in size of this residue by introduction of the Ala
mutation allows helices III and VI to come into closer prox-
imity and to form tighter interactions. These interactions
may then prevent the movements of helices III and VI
required for constitutive activation. Superposition of inactive
A2AR structures (Figure 5) reveals that there is a 1.1 Å move-
ment of helix III towards helix VI in an inactive thermosta-
bilized mutant (containing the V239A mutation) structure
(PDB: 3PWH) compared with the inactive A2AR bound to an
antibody (PDB: 3VG9). This shift of helix III towards helix VI
could explain the formation of the so-called ionic lock
between the E/DRY motif and Glu228, which is not observed
in the antibody-bound structure. The thermostabilized recep-
tor contains other mutations but the only other one likely to
play a role in this shift is the L235A, which is likely to have a
BJPA2AR stability and constitutive activity
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similar effect as the V239A. A potential caveat to this hypoth-
esis is that the presence of the antibody may induce the
differences observed between the two structures.
In summary, the use of the yeast cell growth assay has
allowed a detailed analysis of the pharmacological effects of
receptor mutations since it discriminates between constitu-
tive and agonist-induced receptor signalling events. The
data presented here also provide evidence that the agonist-
induced and constitutively active conformations of the A2AR
are distinct. This information is complementary to, and yet
distinct from, that obtained from the recent high-resolution
structures. Almost all of the GPCR structures obtained so far
are of proteins, which have undergone significant modifica-
tion, and the effects of this on coupling to the downstream
signalling pathway have been largely ignored. The results of
this study show the importance of assessing the effects of
mutations on signalling as well as binding in order to gain a
fuller understanding of the engineered protein structures. In
order to fully understand the mechanism of action of GPCRs,
it will be necessary to functionally and structurally character-
ize all the different active conformations. The research find-
ings are strongly indicative that the yeast cell system is
representative of lower throughput mammalian cell systems,
making it useful for functional studies of mammalian recep-
tors. However, future studies could focus on a detailed com-
parison of the two systems.
The data presented here coupled with the high-resolution
structure information may form the basis of rational design of
receptor-specific drugs that can antagonize constitutive activ-
ity with no effect on agonist-induced activity. In addition,
this work suggests that increased receptor thermostability is
correlated with the loss of constitutive activity. It may be
that the yeast cell growth assay used in combination with
either alanine-scanning mutagenesis or random mutagenesis
methods (Dodevski and Plückthun, 2011) would provide a
powerful screening tool for the production of thermostable
mutants of other GPCRs. Furthermore, by using the yeast
growth assay as an initial screen, it will be possible to select
those mutants that retain some functionality.
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online version of this article at the publisher’s web-site:
Figure S1 (A) NECA-induced activity of the WT A2AR in the
presence of a range of different 3AT concentrations. The
receptor was expressed in the MMY24 Saccharomyces cerevisiae
strain as a construct in the p306GPD vector. (B) Receptor
activation of both WT receptor and an empty vector control
at the optimal concentration of 3AT (5 mM) as determined
in A.
Figure S2 Activity of the WT A2AR in the presence of a range
of different concentrations of an agonist (NECA), and two
inverse agonists GW866133X and GSK124631A with pIC50s
of 9.0 and 8.4 respectively. A neutral compound with no
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effect on A2AR activity, HU210, a CB1 agonist was also added
as a control. The receptor was expressed in the MMY24 Sac-
charomyces cerevisiae strain as a construct in the p306GPD
vector.
Table S1 Mutagenic primers used to generate the single and
double mutant A2AR constructs.
Table S2 Expression levels of the different A2AR + GFP con-
structs in the MMY24 strain. The expression levels of all
constructs were calculated from the relative fluorescence
units as described in Drew et al. (2008). The Bmax values of the
WT, Rant and Rag constructs were assessed by radioligand-
binding analysis of membrane bound receptor.
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